250 Polymorphic Ventricular Tachycardia and Ventricular Fibrillation

Question 1

Polymorphic VT and VF that occur within how many hours of acute MI are associated with greater in-hospital mortality (H20 C250 P1759)

Answer 1

48 h

Question 2

Treatment for supressing recurrent episodes of VT/VF in acquired long QT (H20 C250 P1760)

Answer 2

1-2 g Magnesium sulphate

Question 3

Drug therapy that may be give if magnesium sulphate is insufficient in suppressing PVCs in acquired long QT (H20 C250 P1760)

Answer 3

Isoproterenol

Question 4

Ion channel with most frequently encountered mutations in congenital long QT syndrome (H20 C250 P1760)

Answer 4

Potassium channel

Question 5

Usual trigger of LQTS-1 (H20 C250 P1760)

Answer 5

Exertion, particularly swimming

Question 6

Sudden auditory stimuli or emotional upset predispose arrhythmias in patients with this disease (H20 C250 P1760)

Answer 6

Long QT syndrome 2

Question 7

Genetic mutation in LQTS1 (H20 C250 P1761)

Answer 7

KCNQ1

Question 8

Genetic mutation in LQTS2 (H20 C250 P1761)

Answer 8

KCNH2

Question 9

Genetic mutation in LQTS3 (H20 C250 P1761)

Answer 9

SCN5A

Question 10

Preferred beta-blockers in LQTS 1 or 2 [2] (H20 C250 P1761)

Answer 10

Nadolol, propranolol

Question 11

Rare familial syndrome duento mutations in the cardiac ryanodine receptor or calsequestrin 2 (H20 C250 P1761)

Answer 11

Catecholaminergic polymorphic VT

Question 12

Most common genetic cardiovascular disorder (H20 C250 P1761)

Answer 12

Hypertrophic cardiomyopathy

Question 13

Syncope within how many months is considered a risk factor for sudden death in HCM? (H20 C250 P1761)

Answer 13

6 months

Question 14

Ventricular wall exceeding this thickness is considered a risk factor for sudden death in HCM (H20 C250 P1761)

Answer 14

3 cm